Jiafeng Zou, Yu Yan, Anguo Liu, Haoye Zhang, Zhenguo Liu
{"title":"几丁质酶3样蛋白1与严重非酒精性脂肪肝之间的关系:英国生物银行的一项大型前瞻性队列研究","authors":"Jiafeng Zou, Yu Yan, Anguo Liu, Haoye Zhang, Zhenguo Liu","doi":"10.14309/ctg.0000000000000929","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chitinase-3-like protein 1 (CHI3L1) is a glycoprotein involved in inflammation and fibrosis, but its association with non-alcoholic fatty liver disease (NAFLD) remains unclear. The present study investigated the association between serum CHI3L1 levels and the risk of severe NAFLD in a large prospective cohort.</p><p><strong>Methods: </strong>A prospective cohort study was conducted using UK Biobank data from 50,334 participants. Serum CHI3L1 levels were measured at baseline. Severe NAFLD cases were identified using hospital records. Cox proportional hazards models evaluated the association between CHI3L1 levels and severe NAFLD risk. Restricted cubic spline (RCS) analysis assessed potential non-linearity. Subgroup and mediation analyses were conducted to explore effect modifiers and underlying pathways.</p><p><strong>Results: </strong>Over a median follow-up of 16 years, 766 severe NAFLD cases were identified. Higher CHI3L1 levels were significantly associated with increased severe NAFLD risk (HR = 1.45, 95% CI: 1.34-1.58, P < 0.001). RCS analysis revealed a linear positive association without evidence of non-linearity. Stratified analyses showed consistent associations across subgroups, with no significant interactions. Mediation analysis identified HDL and ALT as partial mediators, explaining 6.38% and 2.86% of the total effect, respectively, while the direct effect of CHI3L1 remained dominant.</p><p><strong>Discussion: </strong>Elevated CHI3L1 levels are associated with an increased risk of severe NAFLD. These findings suggest that CHI3L1 may serve as a novel biomarker and potential contributor to NAFLD progression, offering insights into the inflammatory and metabolic mechanisms underlying the disease.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between chitinase 3-like protein 1 and severe non-alcoholic fatty liver disease: a large prospective cohort study in UK Biobank.\",\"authors\":\"Jiafeng Zou, Yu Yan, Anguo Liu, Haoye Zhang, Zhenguo Liu\",\"doi\":\"10.14309/ctg.0000000000000929\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Chitinase-3-like protein 1 (CHI3L1) is a glycoprotein involved in inflammation and fibrosis, but its association with non-alcoholic fatty liver disease (NAFLD) remains unclear. The present study investigated the association between serum CHI3L1 levels and the risk of severe NAFLD in a large prospective cohort.</p><p><strong>Methods: </strong>A prospective cohort study was conducted using UK Biobank data from 50,334 participants. Serum CHI3L1 levels were measured at baseline. Severe NAFLD cases were identified using hospital records. Cox proportional hazards models evaluated the association between CHI3L1 levels and severe NAFLD risk. Restricted cubic spline (RCS) analysis assessed potential non-linearity. Subgroup and mediation analyses were conducted to explore effect modifiers and underlying pathways.</p><p><strong>Results: </strong>Over a median follow-up of 16 years, 766 severe NAFLD cases were identified. Higher CHI3L1 levels were significantly associated with increased severe NAFLD risk (HR = 1.45, 95% CI: 1.34-1.58, P < 0.001). RCS analysis revealed a linear positive association without evidence of non-linearity. Stratified analyses showed consistent associations across subgroups, with no significant interactions. Mediation analysis identified HDL and ALT as partial mediators, explaining 6.38% and 2.86% of the total effect, respectively, while the direct effect of CHI3L1 remained dominant.</p><p><strong>Discussion: </strong>Elevated CHI3L1 levels are associated with an increased risk of severe NAFLD. These findings suggest that CHI3L1 may serve as a novel biomarker and potential contributor to NAFLD progression, offering insights into the inflammatory and metabolic mechanisms underlying the disease.</p>\",\"PeriodicalId\":10278,\"journal\":{\"name\":\"Clinical and Translational Gastroenterology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14309/ctg.0000000000000929\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000929","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
几丁质酶-3样蛋白1 (CHI3L1)是一种参与炎症和纤维化的糖蛋白,但其与非酒精性脂肪性肝病(NAFLD)的关系尚不清楚。本研究在一个大型前瞻性队列中调查了血清CHI3L1水平与严重NAFLD风险之间的关系。方法:使用英国生物银行50334名参与者的数据进行前瞻性队列研究。基线时测定血清CHI3L1水平。根据医院记录确定严重NAFLD病例。Cox比例风险模型评估了CHI3L1水平与严重NAFLD风险之间的关系。限制三次样条(RCS)分析评估了潜在的非线性。通过亚组分析和中介分析来探讨影响因素和潜在途径。结果:在16年的中位随访中,确定了766例严重NAFLD病例。较高的CHI3L1水平与严重NAFLD风险增加显著相关(HR = 1.45, 95% CI: 1.34-1.58, P < 0.001)。RCS分析显示线性正相关,无非线性证据。分层分析显示,亚组之间存在一致的关联,没有显著的相互作用。中介分析发现HDL和ALT是部分中介,分别占总效应的6.38%和2.86%,而CHI3L1的直接作用仍然占主导地位。讨论:升高的CHI3L1水平与严重NAFLD的风险增加相关。这些发现表明,CHI3L1可能作为一种新的生物标志物和NAFLD进展的潜在因素,为了解该疾病的炎症和代谢机制提供了新的见解。
Association between chitinase 3-like protein 1 and severe non-alcoholic fatty liver disease: a large prospective cohort study in UK Biobank.
Introduction: Chitinase-3-like protein 1 (CHI3L1) is a glycoprotein involved in inflammation and fibrosis, but its association with non-alcoholic fatty liver disease (NAFLD) remains unclear. The present study investigated the association between serum CHI3L1 levels and the risk of severe NAFLD in a large prospective cohort.
Methods: A prospective cohort study was conducted using UK Biobank data from 50,334 participants. Serum CHI3L1 levels were measured at baseline. Severe NAFLD cases were identified using hospital records. Cox proportional hazards models evaluated the association between CHI3L1 levels and severe NAFLD risk. Restricted cubic spline (RCS) analysis assessed potential non-linearity. Subgroup and mediation analyses were conducted to explore effect modifiers and underlying pathways.
Results: Over a median follow-up of 16 years, 766 severe NAFLD cases were identified. Higher CHI3L1 levels were significantly associated with increased severe NAFLD risk (HR = 1.45, 95% CI: 1.34-1.58, P < 0.001). RCS analysis revealed a linear positive association without evidence of non-linearity. Stratified analyses showed consistent associations across subgroups, with no significant interactions. Mediation analysis identified HDL and ALT as partial mediators, explaining 6.38% and 2.86% of the total effect, respectively, while the direct effect of CHI3L1 remained dominant.
Discussion: Elevated CHI3L1 levels are associated with an increased risk of severe NAFLD. These findings suggest that CHI3L1 may serve as a novel biomarker and potential contributor to NAFLD progression, offering insights into the inflammatory and metabolic mechanisms underlying the disease.
期刊介绍:
Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease.
Colon and small bowel
Endoscopy and novel diagnostics
Esophagus
Functional GI disorders
Immunology of the GI tract
Microbiology of the GI tract
Inflammatory bowel disease
Pancreas and biliary tract
Liver
Pathology
Pediatrics
Preventative medicine
Nutrition/obesity
Stomach.